Minimally invasive surgery for advanced gastric cancer
Official title: Laparoscopic and Endoscopic Collaborative Surgery as Rescue-treatment for Advanced Gastric Cancer in Patients Unfit for Surgery - the LE-RACUS Pilot Clinical Study
Run by Region Stockholm · NCT06105515 · Data updated 2026-11-12
This study is testing a new, less invasive surgery for older patients with advanced stomach cancer to see if it can help relieve their symptoms and improve their quality of life.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Region Stockholm Government |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Stockholm) |
| Status | Recruiting |
| Started | April 17, 2024 |
| Main results expected | December 1, 2026 |
| Study ends | February 1, 2027 |
| Registry record updated | July 22, 2025 |
| Trial ID | NCT06105515 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with advanced gastric cancer who are not fit for gastrectomy and have specific tumor characteristics.
✕Probably not a fit
Patients with Borrmann type 4 gastric cancer or tumors located in the cardia may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety and feasibility of Laparoscopic and Endoscopic Collaborative Surgery (LECS) as a less invasive treatment option for patients with advanced gastric cancer who are not candidates for traditional gastrectomy due to age or comorbidities. LECS involves marking the tumor from within using a gastroscope, followed by laparoscopic removal under endoscopic guidance. The goal is to alleviate complications such as bleeding or obstruction caused by the tumor while minimizing surgical trauma. This approach aims to improve the quality of life for frail patients suffering from advanced gastric cancer.
Why it matters
Potential benefit: If successful, this treatment could provide a safer and less invasive option for patients with advanced gastric cancer, improving their quality of life.
How similar studies have gone: While LECS has been used in case reports for palliative treatment, this is the first prospective trial investigating its use for advanced gastric cancer.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * pT2-T4aN0M0 gastric carcinoma * Borrmann type 1-2 \< 5 cm or Borrmann type 3 \< 2 cm * Patient assessment by the multidisciplinary tumor board as not fit for gastrectomy * Signed informed consent Exclusion Criteria: * Borrman type 4 * Location in the cardia
Where it's running
-
Karolinska University Hospital
Stockholm, Sweden Recruiting
Study contacts
- Principal investigator: Ioannis Rouvelas, MD, PhD — ME Övre buk, Karolinska Universitetssjukhuset
- Study coordinator: Ioannis Rouvelas, MD, PhD
- Email: ioannis.rouvals@regionstockholm.se
- Phone: +46707976814
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.